secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forian Inc. (FORA)
CIK:        0001829280
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001140361-23-014013
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forian Q4 revenue up 37% YoY to $7.9M; divests BioTrack for $30M; guides FY2023 rev $20.5-22.5M
--------------------------------------------------------------------------------

- Q4 2022 revenue $7.9M (+37% YoY); net loss $3.6M vs $8.0M; adj. EBITDA -$0.9M vs -$4.5M.
- Full year 2022 revenue $28.0M (+66% YoY); net loss $26.0M vs $26.6M; healthcare info rev grew 130% to $16.4M.
- In February 2023, completed sale of BioTrack for $30M cash, strengthening balance sheet.
- FY2023 guidance: healthcare info rev growth 25-37%, total rev $20.5-22.5M; positive adj. EBITDA expected in H2 2023.
- Cash, equivalents and marketable securities at Dec 31, 2022 were $20.7M, boosted by BioTrack proceeds post-period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829280/000114036123014013/0001140361-23-014013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829280/000114036123014013/brhc10050309_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer